降壓藥對老年高血壓患者動脈彈性功能的影響_《華西醫學》

作者：

趙艷萍 ,  張新軍

四川大學華西醫院老年病科（成都，610041）;

關鍵詞：

老年高血壓藥物治療動脈彈性功能

視頻：

導出 下載 收藏 掃碼 引用

摘要 全文 圖表 視頻 參考文獻 施引文獻 補充材料

老年原發性高血壓患者中，單純收縮期高血壓更常見，是心血管疾病的重要危險因素，主要歸因于彈性動脈僵硬度增加。年齡和血壓水平是影響動脈彈性功能的重要因素，而大動脈彈性功能減退是高血壓患者并發心腦血管意外的重要病理生理基礎，動脈壁結構和功能的改變是高血壓疾病發生發展的早期標志。盡管不同種類降壓藥物在降壓水平上總體差別很小，但對大動脈順應性的改變有所不同。

引用本文： 趙艷萍,張新軍. 降壓藥對老年高血壓患者動脈彈性功能的影響. 華西醫學, 2012, 27(4): 626-629. doi: 復制

1.	王妍, 陶軍, 楊震, 等. 增齡和高血壓病對動脈彈性功能的影響[J]. 中華現代內科學雜志, 2005, 2(9): 769-771.
2.	Tao J, Jin Y, Wang L, et al. In vivo adaptive response of the peripheral conduit artery in patients with borderline systolic hypertension[J]. Chin Med J, 2003, 116(3): 333-336.
3.	王宏宇, 倪永斌, 龔蘭生, 等. 老年高血壓患者大動脈彈性研究[J]. 中國老年學雜志, 2003, 23(1): 10-12.
4.	Mackenzie IS, McEniery CM, Dhakam Z, et al.Comparison of the effects of antihypertensive agents on central blood pressure and arterial stiffness in isolated systolic hypertension[J]. Hypertension, 2009, 54(2): 409-413.
5.	Gasowski J, Fagard RH, Staessen JA, et al. Pulsatile blood pressure component as predictor of mortality in hypertension: a meta-analysis of clinical trial control groups [J]. J Hypertens, 2002, 20(1): 145-151.
6.	Strbova J, Kmecova J, Klimas J. Elevated pulse pressure in treated hypertensive patients during 24-hour ambulatory blood pressure monitoring[J]. Bratisl Lek Listy, 2011, 112(10): 562-567.
7.	張晶, 關欣, 梁伯平, 等. 原發性高血壓患者頸動脈粥樣硬化的臨床意義[J].中國心血管雜志, 2006, 11(4): 286-288.
8.	Lee SW, Hai JJ, Kong SL, et al. Side differences of carotid intima-media thickness in predicting cardiovascular events among patients with coronary artery disease[J]. Angiology, 2011, 62(3): 231-236.
9.	Cohn JN, Finkelstein S, McVeigh G, et al. Noninvasive pulse wave analysis for the early detection of the vascular disease[J]. Hypertension, 1995, 26(3): 503-508.
10.	Gupta V, Sachdeva S, Khan AS, et al. Endothelial dysfunction and inflammation in different stages of essential hypertension[J].Saudi J Kidney Dis Transpl, 2011, 22(1): 97-103.
11.	周淑嫻, 雷娟, 張玉玲, 等. 高血壓患者胰島素抵抗與血清脂聯素及炎癥標志物水平[J]. 中華高血壓雜志, 2008, 16(2): 166-170.
12.	Marchesi C, Paradis P, Schiffrin EL. Role of the rennin-angiotension system in vascular inflammation[J]. Trends pharmacol Sci, 2008, 29(7): 367-374.
13.	Schmieder RE, Hilgers KF, Schlaich MP, et al. Renin-angiotensin system and cardiovascular risk[J]. Lancet, 2007, 369(9568): 1208-1219.
14.	Marketou ME, Kontaraki JE, Tsakountakis NA, et al. Differential effect of telmisartan and amlodipine on monoctyte chemoattractant protein-1 and peroxisome proliferator-activated receptor-gamma gene expression in peripheral monocytes in patients with essential hypertension[J]. Am J Cardiol, 2011, 107(1): 59-63.
15.	Mahmud A, Feely J. Aldosterone-to-renin ratio, arterial stiffness, and the response to aldosterone antagonism in essential hypertension[J].Am J Hypertens, 2005, 18(1): 50-55.
16.	王均生, 劉地川. 貝那普利對原發性高血壓患者腫瘤壞死因子-α、白細胞介素-6和C 反應蛋白的影響[J]. 臨床心血管病雜志, 2011, 27(6): 417-418.
17.	Lchihara A, Hayashi M, Kaneshiro Y, et al. Low doses of losartan and trandolapril improve arterial stiffness in hemodialysis patients[J]. Am J Kidney Dis, 2005, 45(5): 866-874.
18.	Ferguson JM, Minas J, Siapantas S, et al. Effects of a fixed-dose ACE inhibitor-diuretic combination on ambulatory blood pressure and arterial properties in isolated systolic hypertension[J]. J Cardiovasc Pharmacol, 2008, 51(6): 590-595.
19.	Simon AC, Levenson JA, Safar AM, et al. ACE inhibition and brachial artery haemodynamics in hypertension[J].Br J Clin Pharmacol, 1984, 18(Suppl 2): 243-247.
20.	Zou Z, Xi GL, Yuan HB, et al. Telmisartan versus angiotension-converting enzyme inhibitors in the treatment of hypertension: a meta-analysis of randomized controlled trials[J]. J Hum Hypertens, 2009, 23(5): 339-349.
21.	Wang JG, Staessen JA, Li Y, et al. Carotid intima-media thicknedd and antihypertensive treatment: a meta-analysis of randomized controlled trials[J]. Stroke, 2006, 37(7): 1933-1940.
22.	翟麗華, 王沙燕, 梁旭, 等. 氨氯地平逆轉頸動脈內中膜增厚作用與血管緊張素轉換酶基因型的相關性[J]. 中華心血管病雜志, 2008, 36(6): 510-513.
23.	牛紅育, 張麟. 非洛地平緩釋片對老年原發性高血壓患者大動脈順應性的影響[J]. 中華老年心腦血管病雜志, 2010, 12(4): 316-318.
24.	Dahlöf B, Devereux RB, Kjeldsen SE, et al. Cardiovascular mobidity and mortality in the Losartan Intervention for Endpoint Reduction in Hypertension Study (LIFE): a randomized trial against atenolol[J]. Lancet, 2002, 359(9311): 995-1003.
25.	Dahlöf B, Sever PS, Poulter NR, et al. Prevention of cardiovascular events with an antihypertensive regimen ofamlodipine adding perindopril as required versus atenolol addingbendroflumethiazide as required, in the Anglo-Scandinavian Cardiac OutcomesTrial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial [J]. Lancet, 2005, 366(9489): 895-906.
26.	Bradley HA, Wiysonge CS, Volmink JA. How strong is the evidence for use of beta-blockers as first-line therapy for hypertension？ Systematic review and meta-analysis[J]. Hypertension, 2006, 24(11): 2131-2141.
27.	Lindholm LH, Carlberg B, Samuelsson O. Should βblockers remain first choice in the treatment of primary hypertension? A meta-analysis[J]. Lancet, 2005, 366(9496): 1545-1553.
28.	Schiffrin EL, Pu Q, Park JB. Effect of amlodipine compared to atenolol on small arteries of previously untreated essential hypertension patients[J]. Am J Hypertens, 2002, 15(2 Pt 1): 105-110.
29.	Schiffrin EL, Park JB, Pu Q. Effect of crossing over hypertensive patients from a beta-blocker to an angiotensin receptor antagonist on resistance artery structure and on endothelial function[J]. J Hypertens, 2002, 20(1): 71-78.
30.	Ferguson JM, Lustermans FA, Breed JG, et al. The influence of perindopril and the diuretic combination amiloride+hydrochlorothiazide on the vessel wall properties of large arteries in hypertensive patients[J]. J Hypertens, 1995, 13(8): 839-848.
31.	中華醫學會心血管病學分會高血壓學組. 利尿劑治療高血壓的中國專家共識[J]. 中華高血壓雜志, 2011, 19(3): 214-222.

1. 　王妍, 陶軍, 楊震, 等. 增齡和高血壓病對動脈彈性功能的影響[J]. 中華現代內科學雜志, 2005, 2(9): 769-771.
2. 　Tao J, Jin Y, Wang L, et al. In vivo adaptive response of the peripheral conduit artery in patients with borderline systolic hypertension[J]. Chin Med J, 2003, 116(3): 333-336.
3. 　王宏宇, 倪永斌, 龔蘭生, 等. 老年高血壓患者大動脈彈性研究[J]. 中國老年學雜志, 2003, 23(1): 10-12.
4. 　Mackenzie IS, McEniery CM, Dhakam Z, et al.Comparison of the effects of antihypertensive agents on central blood pressure and arterial stiffness in isolated systolic hypertension[J]. Hypertension, 2009, 54(2): 409-413.
5. 　Gasowski J, Fagard RH, Staessen JA, et al. Pulsatile blood pressure component as predictor of mortality in hypertension: a meta-analysis of clinical trial control groups [J]. J Hypertens, 2002, 20(1): 145-151.
6. 　Strbova J, Kmecova J, Klimas J. Elevated pulse pressure in treated hypertensive patients during 24-hour ambulatory blood pressure monitoring[J]. Bratisl Lek Listy, 2011, 112(10): 562-567.
7. 　張晶, 關欣, 梁伯平, 等. 原發性高血壓患者頸動脈粥樣硬化的臨床意義[J].中國心血管雜志, 2006, 11(4): 286-288.
8. 　Lee SW, Hai JJ, Kong SL, et al. Side differences of carotid intima-media thickness in predicting cardiovascular events among patients with coronary artery disease[J]. Angiology, 2011, 62(3): 231-236.
9. 　Cohn JN, Finkelstein S, McVeigh G, et al. Noninvasive pulse wave analysis for the early detection of the vascular disease[J]. Hypertension, 1995, 26(3): 503-508.
10. 　Gupta V, Sachdeva S, Khan AS, et al. Endothelial dysfunction and inflammation in different stages of essential hypertension[J].Saudi J Kidney Dis Transpl, 2011, 22(1): 97-103.
11. 　周淑嫻, 雷娟, 張玉玲, 等. 高血壓患者胰島素抵抗與血清脂聯素及炎癥標志物水平[J]. 中華高血壓雜志, 2008, 16(2): 166-170.
12. 　Marchesi C, Paradis P, Schiffrin EL. Role of the rennin-angiotension system in vascular inflammation[J]. Trends pharmacol Sci, 2008, 29(7): 367-374.
13. 　Schmieder RE, Hilgers KF, Schlaich MP, et al. Renin-angiotensin system and cardiovascular risk[J]. Lancet, 2007, 369(9568): 1208-1219.
14. 　Marketou ME, Kontaraki JE, Tsakountakis NA, et al. Differential effect of telmisartan and amlodipine on monoctyte chemoattractant protein-1 and peroxisome proliferator-activated receptor-gamma gene expression in peripheral monocytes in patients with essential hypertension[J]. Am J Cardiol, 2011, 107(1): 59-63.
15. 　Mahmud A, Feely J. Aldosterone-to-renin ratio, arterial stiffness, and the response to aldosterone antagonism in essential hypertension[J].Am J Hypertens, 2005, 18(1): 50-55.
16. 　王均生, 劉地川. 貝那普利對原發性高血壓患者腫瘤壞死因子-α、白細胞介素-6和C 反應蛋白的影響[J]. 臨床心血管病雜志, 2011, 27(6): 417-418.
17. 　Lchihara A, Hayashi M, Kaneshiro Y, et al. Low doses of losartan and trandolapril improve arterial stiffness in hemodialysis patients[J]. Am J Kidney Dis, 2005, 45(5): 866-874.
18. 　Ferguson JM, Minas J, Siapantas S, et al. Effects of a fixed-dose ACE inhibitor-diuretic combination on ambulatory blood pressure and arterial properties in isolated systolic hypertension[J]. J Cardiovasc Pharmacol, 2008, 51(6): 590-595.
19. 　Simon AC, Levenson JA, Safar AM, et al. ACE inhibition and brachial artery haemodynamics in hypertension[J].Br J Clin Pharmacol, 1984, 18(Suppl 2): 243-247.
20. 　Zou Z, Xi GL, Yuan HB, et al. Telmisartan versus angiotension-converting enzyme inhibitors in the treatment of hypertension: a meta-analysis of randomized controlled trials[J]. J Hum Hypertens, 2009, 23(5): 339-349.
21. 　Wang JG, Staessen JA, Li Y, et al. Carotid intima-media thicknedd and antihypertensive treatment: a meta-analysis of randomized controlled trials[J]. Stroke, 2006, 37(7): 1933-1940.
22. 　翟麗華, 王沙燕, 梁旭, 等. 氨氯地平逆轉頸動脈內中膜增厚作用與血管緊張素轉換酶基因型的相關性[J]. 中華心血管病雜志, 2008, 36(6): 510-513.
23. 　牛紅育, 張麟. 非洛地平緩釋片對老年原發性高血壓患者大動脈順應性的影響[J]. 中華老年心腦血管病雜志, 2010, 12(4): 316-318.
24. 　Dahlöf B, Devereux RB, Kjeldsen SE, et al. Cardiovascular mobidity and mortality in the Losartan Intervention for Endpoint Reduction in Hypertension Study (LIFE): a randomized trial against atenolol[J]. Lancet, 2002, 359(9311): 995-1003.
25. 　Dahlöf B, Sever PS, Poulter NR, et al. Prevention of cardiovascular events with an antihypertensive regimen ofamlodipine adding perindopril as required versus atenolol addingbendroflumethiazide as required, in the Anglo-Scandinavian Cardiac OutcomesTrial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial [J]. Lancet, 2005, 366(9489): 895-906.
26. 　Bradley HA, Wiysonge CS, Volmink JA. How strong is the evidence for use of beta-blockers as first-line therapy for hypertension？ Systematic review and meta-analysis[J]. Hypertension, 2006, 24(11): 2131-2141.
27. 　Lindholm LH, Carlberg B, Samuelsson O. Should βblockers remain first choice in the treatment of primary hypertension? A meta-analysis[J]. Lancet, 2005, 366(9496): 1545-1553.
28. 　Schiffrin EL, Pu Q, Park JB. Effect of amlodipine compared to atenolol on small arteries of previously untreated essential hypertension patients[J]. Am J Hypertens, 2002, 15(2 Pt 1): 105-110.
29. 　Schiffrin EL, Park JB, Pu Q. Effect of crossing over hypertensive patients from a beta-blocker to an angiotensin receptor antagonist on resistance artery structure and on endothelial function[J]. J Hypertens, 2002, 20(1): 71-78.
30. 　Ferguson JM, Lustermans FA, Breed JG, et al. The influence of perindopril and the diuretic combination amiloride+hydrochlorothiazide on the vessel wall properties of large arteries in hypertensive patients[J]. J Hypertens, 1995, 13(8): 839-848.
31. 　中華醫學會心血管病學分會高血壓學組. 利尿劑治療高血壓的中國專家共識[J]. 中華高血壓雜志, 2011, 19(3): 214-222.

《華西醫學》

降壓藥對老年高血壓患者動脈彈性功能的影響

摘要 全文 圖表 視頻 參考文獻 施引文獻 補充材料

Format

Content

《華西醫學》

降壓藥對老年高血壓患者動脈彈性功能的影響

摘要 全文 圖表 視頻 參考文獻 施引文獻 補充材料

Format

Content

摘要全文圖表視頻參考文獻施引文獻補充材料